- Home
- TCMD vs ZURA Comparison
TCMD vs ZURA Comparison
Compare TCMD & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCMD | ZURA |
|---|---|---|
| Founded | 1995 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 549.2M | 521.8M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | TCMD | ZURA |
|---|---|---|
| Price | $25.15 | $5.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $36.00 | $13.00 |
| AVG Volume (30 Days) | 202.3K | ★ 623.5K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.14 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.60 | N/A |
| Revenue Next Year | $9.14 | N/A |
| P/E Ratio | $30.12 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.61 | $0.99 |
| 52 Week High | $37.77 | $7.25 |
Technical Indicators
Market Signals| Indicator | TCMD | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 43.81 | 44.86 |
| Support Level | $24.54 | $5.35 |
| Resistance Level | $25.42 | $5.75 |
| Average True Range (ATR) | 0.95 | 0.33 |
| MACD | 0.17 | -0.01 |
| Stochastic Oscillator | 58.97 | 40.47 |
Price Performance
Historical ComparisonAbout TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.